2030년까지 북미 전염병 치료제 시장 예측 - 지역 분석 - 약물 종류별(항바이러스제, 항균제, 항진균제 등), 적응증(HIV, 간염, 결핵, 인플루엔자, HPV 및 기타), 경로별 투여(경구, 비경구, 국소 및 기타) 및 유통 경로(병원 약국, 소매 약국 및 기타)
감염병 유병률 증가로 북미 전염병 치료제 시장
감염병은 바이러스, 기생충, 박테리아, 곰팡이, 독성 제품 및 기타 감염원. HIV는 전 세계적으로 주요 공중 보건 문제입니다. UNAIDS(United Nations Programme on HIV/AIDS)에 따르면 2020년 기준 약 3,770만 명이 HIV에 감염되었습니다. 이 중 3,600만 명이 성인이었고, 170만 명이 0~14세 어린이였습니다. 또한 절반 이상(53%)이 소녀와 여성이었습니다. 또한 2020년에는 전 세계적으로 150만 건의 새로운 HIV 사례가 보고되었습니다. 마찬가지로, 간염은 바이러스 감염으로 인한 간의 감염입니다. 간염 바이러스의 주요 유형은 A, B, C, D, E입니다. 세계보건기구(WHO)에 따르면 전 세계적으로 약 5,800만 명이 만성 C형 간염 바이러스 감염으로 고통 받고 있으며, 매년 약 150만 명이 감염되고 있습니다. 새로운 감염이 발생합니다.
WHO에 따르면 결핵(TB)은 전 세계적으로 사망 원인 13위이며, 코로나19에 이어 두 번째로 많은 전염병입니다. 2020년에는 결핵으로 인해 150만 명이 사망했습니다(HIV에 감염된 214,000명 포함). 또한, 2020년에는 전 세계적으로 1,000만 명이 결핵에 걸렸으며 그 중 어린이는 110만 명, 여성은 330만 명, 남성은 560만 명이었습니다. 더욱이, 병원 획득 감염 또는 의료 관련 감염(HAI)은 이환율과 사망률이 높습니다. 또한, 의료 시스템에 대한 지출은 매년 막대합니다. 질병통제예방센터(CDC)는 HAI가 미국 병원에서 매년 약 170만 건의 감염 사례와 99,000명의 사망자를 발생시킨다고 보고했습니다. 따라서 전 세계적으로 전염병의 확산이 증가함에 따라 전염병 치료제 시장의 성장이 촉진되고 있습니다.
북미 감염병 치료제 시장 개요
북미 감염병 치료제 시장은 미국, 캐나다, 멕시코로 구분됩니다. 북미는 2022년 세계 시장에서 가장 큰 점유율을 차지했습니다. 기술 발전의 채택이 증가하고 연구 개발 활동이 증가하면서 전염병 치료제 시장의 성장이 가속화될 것으로 예상됩니다. 더욱이, 대규모 의료 사업과 만성 질환 및 바이러스성 질환 치료를 위한 첨단 치료 솔루션에 대한 수요 증가로 인해 이 지역의 시장 확장이 촉진되고 있습니다. 항바이러스 치료법의 채택 증가로 인해 항바이러스제에 대한 수요가 급증하면서 미국 시장이 성장할 것으로 예상됩니다. 주요 제약·바이오제약 기업들은 항바이러스제 제조 역량 확대에 주력하고 있다. 예를 들어, 캘리포니아에 있는 Gilead Sciences, Inc.는 2020년 5월에 코로나19 치료를 위한 연구용 항바이러스제인 Remdesivir에 대해 FDA 승인을 받았습니다. 또한 2022년 4월에 미국 식품의약국(FDA)은 보충 신약을 승인했습니다. 28일 이상, 체중 3kg 이상, 코로나19 치료를 위해 입원했거나 경증~중등도 코로나19 감염이 있는 소아 환자 치료를 위한 베클루리(렘데시비르)에 대한 길리어드 사이언스의 신청(sNDA). 2021년 9월 바이든-해리스 행정부는 미국의 공중 보건 및 의료 부문 전반에 걸쳐 감염 통제 및 예방 활동을 개선하기 위해 질병통제예방센터(CDC)를 통해 21억 달러를 투자했습니다. 이러한 요인들은 예측 기간 동안 미국 전염병 치료제 시장 성장을 촉진할 것으로 예상됩니다.
2030년까지 북미 감염성 질환 치료제 시장 수익 및 예측(미화 백만 달러)
북미 감염성 질환 치료제 시장 세분화
북미 감염성 질환 치료제 시장은 다음과 같이 분류됩니다. 의약품 종류, 적응증, 투여경로, 유통경로, 국가 등으로 구분됩니다.
약물 종류에 따라 북미 전염병 치료제 시장은 항바이러스제, 항균제, 항진균제 등으로 분류됩니다. 항바이러스제 부문은 2022년 가장 큰 시장 점유율을 차지했습니다.
적응증 측면에서 북미 감염병 치료제 시장은 HIV, 간염, 결핵, 인플루엔자, HPV 등으로 분류됩니다. HIV는 2022년에 가장 큰 시장 점유율을 차지했습니다.
투여 경로에 따라 북미 전염병 치료제 시장은 경구, 비경구, 국소 등으로 분류됩니다. 경구 부문은 2022년 가장 큰 시장 점유율을 차지했습니다.
유통 채널 측면에서 북미 감염병 치료제 시장은 병원 약국, 소매 약국 등으로 분류됩니다. 2022년에는 병원 약국이 가장 큰 시장 점유율을 차지했습니다.
국가별로 북미 감염병 치료제 시장은 미국, 캐나다, 멕시코로 분류됩니다. 미국은 2022년 북미 전염병 치료제 시장 점유율을 장악했습니다.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, Pfizer Inc 및 Shionogi & Co Ltd는 북미 전염병 치료제 시장에서 활동하는 선도적인 회사 중 일부입니다.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 North America Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Growing Opportunities in Developing Nations
4.4.2 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - North America Market Analysis
5.1 North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. North America Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. North America Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. North America Infectious Disease Therapeutics Market - Country Analysis
10.1 North America Infectious Disease Therapeutics Market Overview
10.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.3 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 United States: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 United States: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.3.3 United States: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.4 United States: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.4 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.5 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Canada: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.5.2 Canada: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.5.3 Canada: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.5.4 Canada: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.6 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.7 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 Mexico: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.7.2 Mexico: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.7.3 Mexico: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.7.4 Mexico: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Shionogi & Co Ltd
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bayer AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 BioCryst Pharmaceuticals Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 GSK Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 AbbVie Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Merck & Co Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Astellas Pharma Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. North America Infectious Disease Therapeutics Market Segmentation
Table 2. Diseases and Funding
Table 3. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 4. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 5. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 6. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 7. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
Table 8. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 9. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 10. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 11. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 12. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 13. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 14. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 15. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 17. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 18. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 19. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 20. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 21. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
List of Figures
Figure 1. North America Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. North America Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. North America Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. North America Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. North America Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Growth Strategies in the Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. BioCryst Pharmaceuticals Inc
5. F. Hoffmann-La Roche Ltd
6. Gilead Sciences Inc
7. GSK Plc
8. Merck & Co Inc
9. Pfizer Inc
10. Shionogi & Co Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America infectious disease therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America infectious disease therapeutics market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.